Baker Hughes data show U.S. total weekly active drilling-rig count up 6 at 610
(END) Dow Jones Newswires
January 28, 2022 13:03 ET (18:03 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Enzolytics, Inc. is a drug development biotechnology company. The Company is engaged in the commercialization of its proteins for the treatment of debilitating infectious diseases. The Company is focused in developing monoclonal antibody therapy and treating infectious diseases. It has anti-HIV therapeutics and a methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested anti-HIV therapeutics. The Company has developed a cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus. The Company has also created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus, and diphtheria. The Company is testing these antibodies to prepare them for use as therapies against these diseases.
|
|
|
|
|
(END) Dow Jones Newswires
January 28, 2022 13:03 ET (18:03 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2022. All rights reserved.